Research on high-risk cancers will be the focus of a new partnership between pharmaceutical company Bristol-Myers Squibb Co. and the Dana-Farber Cancer Institute, a cancer treatment and research center in Boston that is a principal teaching affiliate of Harvard Medical School.
The collaboration is part of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program, which is sponsored by the U.S. government. Its goal is to use clinical investigation of immuno-oncology therapeutics to develop possible therapies for patients with high risk or poor prognostic cancers.
Dana-Farber Cancer Institute is now one of a group of academic-based cancer centers to become part of the I-O RPM program.
